Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective

被引:13
作者
Zhang, P. -F [1 ,2 ,3 ]
Wen, F. [1 ,2 ,3 ]
Zhou, J. [1 ,2 ,3 ]
Huang, J. -X. [1 ,2 ,3 ]
Zhou, K. -X. [1 ,2 ,3 ]
Wu, Q. -J. [1 ,2 ,3 ]
Wang, X. -Y. [1 ,2 ,3 ]
Zhang, M. -X. [1 ,2 ,3 ]
Liao, W. -T. [1 ,2 ,3 ]
Li, Q. [1 ,2 ,3 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Med Oncol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, West China Sch Med, West China Biomed Big Data Ctr, Chengdu, Peoples R China
关键词
Cost-effectiveness; Capecitabine; Bevacizumab; Elderly patients; Colorectal cancer; 1ST-LINE TREATMENT; PHASE-III; DECISION-MAKING; OPEN-LABEL; CHEMOTHERAPY; FLUOROURACIL; COMBINATION; SURVIVAL; LEUCOVORIN; STATISTICS;
D O I
10.1007/s12094-019-02114-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The aim of the study was to evaluate the cost-effectiveness of capecitabine plus bevacizumab compared with capecitabine alone in elderly patients with metastatic colorectal cancer (CRC) from a Chinese societal perspective. Methods A decision-analytic Markov model was conducted to simulate the process of metastatic CRC. Three distinct health states: progression-free survival (PFS), progressive disease and death were included. Clinical data were derived from the AVEX trial. Health effectiveness was denoted in quality-adjusted life years (QALYs) and health utilities were derived from previously published studies. Incremental cost-effectiveness ratio (ICER) was regarded as the primary endpoint and willingness-to-pay (WTP) threshold was set at $26,753.37/QALY (3 x per capita GDP of China, 2017). One-way sensitivity analyses and probabilistic sensitivity analysis were also performed to explore the parameters uncertainty in the study. Results Over a 10-year life horizon, capecitabine plus bevacizumab gained 1.14 QALYs at an average cost of $21,609.48, while the effectiveness and cost of capecitabine group were 0.99 QALYs and $7274.83, respectively. The ICER between the two groups was $95,564.33/QALY. Parameters that mostly influenced the results of the model were utility of PFS state, duration of PFS state for capecitabine plus bevacizumab, total cost of PFS state for capecitabine plus bevacizumab and price of bevacizumab. The probabilities of capecitabine plus bevacizumab and capecitabine as the dominant option were 0% and 100% at the WTP threshold of $26,753.37/QALY. Conclusions The results of the study showed that capecitabine plus bevacizumab is unlikely to be a cost-effective treatment option for elderly patients with metastatic CRC.
引用
收藏
页码:103 / 110
页数:8
相关论文
共 42 条
[1]  
[Anonymous], TARGETED THERAPY ADV
[2]  
[Anonymous], 55 MEA
[3]   Bevacizumab plus chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results [J].
Aparicio, T. ;
Bouche, O. ;
Taieb, J. ;
Maillard, E. ;
Kirscher, S. ;
Etienne, P. -L. ;
Faroux, R. ;
Akouz, F. Khemissa ;
El Hajbi, F. ;
Locher, C. ;
Rinaldi, Y. ;
Lecomte, T. ;
Lavau-Denes, S. ;
Baconnier, M. ;
Oden-Gangloff, A. ;
Genet, D. ;
Paillaud, E. ;
Retornaz, F. ;
Francois, E. ;
Bedenne, L. .
ANNALS OF ONCOLOGY, 2018, 29 (01) :133-138
[4]   Colorectal cancer care in elderly patients: Unsolved issues [J].
Aparicio, Thomas ;
Pamoukdjian, Frederic ;
Quero, Laurent ;
Manfredi, Sylvain ;
Wind, Philippe ;
Paillaud, Elena .
DIGESTIVE AND LIVER DISEASE, 2016, 48 (10) :1112-1118
[5]   Geriatric Factors Predict Chemotherapy Feasibility: Ancillary Results of FFCD 2001-02 Phase III Study in First-Line Chemotherapy for Metastatic Colorectal Cancer in Elderly Patients [J].
Aparicio, Thomas ;
Jouve, Jean-Louis ;
Teillet, Laurent ;
Gargot, Dany ;
Subtil, Fabien ;
Le Brun-Ly, Valerie ;
Cretin, Jacques ;
Locher, Christophe ;
Bouche, Olivier ;
Breysacher, Gilles ;
Charneau, Jacky ;
Seitz, Jean-Francois ;
Gasmi, Mohamed ;
Stefani, Laetitia ;
Ramdani, Mohamed ;
Lecomte, Thierry ;
Mitry, Emmanuel .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) :1464-1470
[6]   A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model [J].
Blommestein, Hedwig M. ;
Verelst, Silvia G. R. ;
de Groot, Saskia ;
Huijgens, Peter C. ;
Sonneveld, Pieter ;
Uyl-de Groot, Carin A. .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (02) :198-208
[7]   The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study [J].
Carter, Hannah E. ;
Zannino, Diana ;
Simes, R. John ;
Schofield, Deborah J. ;
Howard, Kirsten ;
Zalcberg, John R. ;
Price, Timothy J. ;
Tebbutt, Niall C. .
EUROPEAN JOURNAL OF CANCER, 2014, 50 (03) :535-543
[8]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[9]   Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis [J].
Ciaccio, Antonio ;
Cortesi, Paolo A. ;
Bellelli, Giuseppe ;
Rota, Matteo ;
Conti, Sara ;
Okolicsanyi, Stefano ;
Rota, Monica ;
Cesana, Giancarlo ;
Mantovani, Lorenzo G. ;
Annoni, Giorgio ;
Strazzabosco, Mario .
LIVER INTERNATIONAL, 2017, 37 (07) :982-994
[10]   Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial [J].
Cunningham, David ;
Lang, Istvan ;
Marcuello, Eugenio ;
Lorusso, Vito ;
Ocvirk, Janja ;
Shin, Dong Bok ;
Jonker, Derek ;
Osborne, Stuart ;
Andre, Niko ;
Waterkamp, Daniel ;
Saunders, Mark P. .
LANCET ONCOLOGY, 2013, 14 (11) :1077-1085